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Lessons From Macrolide Antibiotics*Sami Viskin, MD,y Ofer Havakuk, MD,y Mitchell J. Schwaber, MD, MSCyzS udden death resulting from medicationsprescribed with good intentions is an ever-present threat ﬁrst recognized nearly a century
ago (1,2). As early as 1923, when quinidine was ﬁrst
used as antiarrhythmic therapy, a disturbing phe-
nomenon was noted: some patients treated with
quinidine suffered from sudden collapses, sometimes
ending in unexpected deaths (2). These events were
ﬁrst attributed to “embolism” (2) or “nervous-system
depression” (1). It was only in 1964, when Selzer and
Wray (3) ﬁrst documented polymorphic ventricular
tachyarrhythmias (VTA) as the cause for quinidine
syncope.
The phenomenon of “drug-induced arrhythmia”
became even more puzzling when medications with
no cardiac indications, understandably assumed to
be free of cardiac effects, were also reported to pro-
voke arrhythmia (4). The ﬁrst medication was the
antipsychotic thioridazine. In 1966, Schoonmaker
et al. (4) described a patient with schizophrenia
who had normal QT at baseline but developed QT
prolongation during thioridazine therapy. This
thioridazine-induced QT prolongation “resembled
quinidine effect” and was therefore considered
benign, so when the patient developed polymorphic
VTA, he was treated with no other but quinidine (he
eventually survived thanks to cardiac pacing) (4).
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this paper to disclose.understanding of the disease mechanism in those
days. It would take an additional 20 years to even-
tually demonstrate that quinidine prolongs the action
potential, thereby prolonging the QT interval, by
blocking myocardial cell channels responsible for the
potassium outﬂow current now known as delayed-
rectiﬁer potassium current (IKr) (5). Since then, the
list of medications with IKr channel blocking proper-
ties linked to a drug-induced long QT syndrome
(LQTS) has steadily grown to include medications as
varied as antibiotics and antiallergy remedies (6). For
these medications, their potency as IKr channel
blockers in experimental studies correlates with their
pro-arrhythmic potential (7). This experimental-to-
clinical correlation is not perfect because, in addition
to patient-speciﬁc characteristics that inﬂuence the
risk for VTA (see the following text), drugs prolong the
QT interval by mechanisms other than “simple” IKr
channel blockade. Drugs may disrupt the trafﬁcking of
newly created IKr protein from the endoplasmic retic-
ulum to the cell membrane, thereby reducing IKr
channel expression (8), or they might increase the
highly torsadogenic late-sodium current INa-L (9).
Drug-induced LQTS is a nightmare for the pharma-
ceutical industry; it is among the most common causes
of the withdrawal of drugs. Such was the case for ter-
fenadine, the ﬁrst nonsedating antihistamine, with-
drawn from the market when it was 1 of the most
frequently prescribed drugs in the world (10). An
unkinder fate awaited grepaﬂoxacin, a newly devel-
oped quinolone antibiotic predicted to generate $1
billion, which was taken off the market shortly after its
ﬁrst release, following public accusations against the
manufacturer and the Food and Drug Administration
(11). Drug-induced LQTS is an even worse nightmare
for physicians because we are the ones prescrib-
ing clinically indicated “noncardiac medications,”
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2186knowing that our treatment carries a small risk of
provoking VTA. Not knowing how small this “small
risk” really is has probablymade this dilemma easier to
cope with. Not anymore..SEE PAGE 2173HOW SMALL IS “SMALL”?
In this issue of the Journal, Cheng et al. (12) provide
robust estimates of the scale of the arrhythmia risk
associated with antibiotic treatment with erythro-
mycin and related macrolide antibiotics. Cheng et al.
(12) collected data for >20 million patients partici-
pating in 33 studies that compared patients treated
with macrolide antibiotics to similar patients treated
otherwise. Eleven studies (with 6 million patients)
provided data for sudden death or VTA (12). The
cohort of patients not taking macrolides experienced
an average of 80 cases of sudden death or VTA per
million treatment courses. Compared with no
macrolide use, current macrolide treatment was
associated with an additional 118 cases of sudden
death or VTA, or 36 additional sudden deaths, per
million treatment courses. Simply put, roughly
1:8,500 patients treated with a macrolide antibiotic
is expected to develop a serious arrhythmic event,
and 1:30,000 could die suddenly, because of our
treatment. This distressing statement, as opposed to
a more palatable announcement that macrolide
therapy is associated with increased risk of
arrhythmic death, is justiﬁable despite the observa-
tional nature of the present study because: 1) the
pro-arrhythmic mechanism of macrolides is already
well established (13); and 2) a 2-fold increased risk
for VTA among patients treated with macrolides also
existed in prospective randomized controlled studies
(12). Importantly, patients treated with penicillin/
amoxicillin had no increased risk of VTA in com-
parison to patients taking no antibiotic therapy,
whereas macrolide therapy increased the arrhythmic
risk not only in comparison to no therapy but also in
comparison to penicillin/amoxicillin (12), dispersing
the confounding effects of infection. Finally, data on
total mortality were available for >12 million pa-
tients from 23 studies, and overall, macrolide use
was not statistically associated with an increased
risk of death (12), denoting the small absolute risk of
arrhythmic death.
DRUG-INDUCED LONG QT SYNDROME:
DON’T ASK, DON’T TELL?
The 1:30,000 iatrogenic arrhythmia death risk re-
ported by Cheng et al. (12) cannot be simply sweptunder the carpet. The pharmaceutical industry will
now be more vulnerable to litigation, and this could
persuade them to discontinue the production of
macrolides. This would be unfortunate because
macrolides are ﬁrst-line agents for community-
acquired pneumonia, legionellosis, sexually trans-
mitted infections, and peptic ulcer caused by
Helicobacter pylori infection. Alternative antibiotics
exist but have their own pitfalls, including
increasing worldwide spread of resistance to quino-
lones (14). Treating infections in young children and
pregnant women, for which some macrolides are
approved but quinolones and tetracyclines are not,
would become challenging, as would treatment of
streptococcal pharyngitis in the b-lactam-allergic
patient. Although there have been antibiotics
removed from use, these have been individual
agents (e.g., methicillin), rather than an entire class.
One might argue that the drop in use of chloram-
phenicol because of rare hematologic toxicity rep-
resents the stoppage of an entire class, yet the 1950s,
when chloramphenicol bone marrow toxicity was
reported, was a time of ongoing introduction of new
antibiotics. Today, when antimicrobial resistance
represents a major threat to global health and new
treatment options are frighteningly few (14), losing
an entire class of antibiotics would represent a major
setback in the ﬁght against infections. Furthermore,
it takes years to fully understand the consequences
of a drug’s disappearance. In 1990, a meta-analysis
showed that quinidine prevents atrial ﬁbrillation at
the expense of increased mortality (15). The ensuing
decline in demand for this product contributed to
the decision by its main manufacturer to discontinue
the production of quinidine (16). By the time we
realized quinidine is practically the only effective
therapy for preventing VTA related to Brugada syn-
drome and early repolarization syndromes, patients
faced a grim worldwide shortage of this life-saving
medication (17).
The 1:30,000 increased risk of sudden death from
macrolides must be seen in the context of other iat-
rogenic complications: drug-induced fulminant hep-
atitis occurs in 1:8,000 patients and is fatal in
1:50,000 (18), whereas 1:5,000 patients treated with
penicillin or with aspirin develop anaphylaxis that is
fatal in 1:50,000 (19). The risk for drug-induced LQTS,
rare as it is, may be further reduced by screening for
well-recognized risk factors (20). A decade ago, we
reported that 70% of all published cases of drug-
induced LQTS from “noncardiac medications”
had $2 easily identiﬁable risk factors: female heart
disease, hypokalemia or drug toxicity from excessive
dosages or drug interactions (21). Prescription for
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2187$2 IKr blockers was common in patients with drug-
induced VTA, involving (for example) treatment of
“allergic bronchitis” with nonsedating antihistamines
and macrolides. It is therefore critical to instruct all
patients receiving QT-prolonging medications to
meticulously avoid additional IKr blockers. Avoidance
of drug combinations that could lead to toxic levels
by competing for the same metabolic pathway is also
important now that 20% of all patients receive >5
medications simultaneously (22). Women not only
receive polypharmacy more often than men (22), they
are also more likely to develop VTA from QT-
prolonging medications (21). Computerized prescrip-
tion support tools, with alerts to potential adverse
drug interactions, should integrate data on drug
metabolism and pro-arrhythmic potential.
Electrocardiographic (ECG) screening and ECG
monitoring are recommended for hospitalized pa-
tients receiving speciﬁc QT-prolonging medications
(20) and for out-of-hospital initiation of QT-
prolonging antiarrhythmia drugs (23). However, no
such recommendations exist for QT-prolonging
“noncardiac” medications prescribed in primary-
care settings, mainly because it is considered
impractical. Exceptions exist: 1) the Center for Sub-
stance Abuse Treatment called for ECG surveillance of
patients treated with methadone (24), a QT-
prolonging drug that is exceptional because it is
prescribed for very long-term use (for opioid depen-
dence); 2) the United Kingdom National Health Ser-
vice instructs physicians to consider ECG surveillance
during treatment with QT-prolonging medications of
patients with risk factors for drug-induced LQTS. In
addition, an increasing number of drug manufac-
turers now include drug-label warnings recommend-
ing ECG recordings before the prescription of “risky”
medications. On the other hand, a recent survey of
patients beginning out-of-hospital therapy with
haloperidol (an antipsychotic agent associated with
drug-induced LQTS) found that only 2% of patients
had an ECG recorded at the onset of therapy (25).FOR THE TIMES THEY ARE A-CHANGIN’
Patients’ transtelephonic ECG monitoring from
home for QT-monitoring, using small dedicated de-
vices (26) or even mobile phones, is feasible and
could be offered to high-risk patients. True, most
physicians cannot recognize a long QT (27), but that
can be changed with proper training (28). Alterna-
tively, dedicated services of home-QT-monitoring
could be offered. The technological obstacles, how-
ever, are only part of the problem. Although the risk
for drug-induced VTA increases as the QT prolongs,
there is no absolute cutoff value. For example,
among 5,000 patients receiving azimilide, the risk
for VTA rose as the QTc increased >500 ms and then
increased rapidly with a QTc >520 ms (29); yet, 45%
and 60% of patients with VTA had a QTc below
these 2 cutoff values (29). Finally, full disclosure of
the available information could prove counterpro-
ductive by lessening therapeutic compliance (30). In
other words, the perception that “this drug could
kill you” could lead to premature treatment
discontinuation, with serious consequences. No
doubt, drug-induced LQTS has no easy solutions.
And there is more; long-term use of nortriptyline
(an antidepressant that blocks the cardiac sodium
channel) is associated with a 5-fold increased risk of
sudden death by means of a lesser known form of
pro-arrhythmia: drug-induced Brugada syndrome
(31). Given the omnipresence of practice guidelines
issued by authoritative organizations (i.e., American
College of Cardiology/American Heart Association)
dealing with just about every topic in cardiology, it
is time for a consensus paper on how to deal with
these controversies.
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